Search

Your search keyword '"Yokoi, Chizu"' showing total 228 results
Start Over Author "Yokoi, Chizu" Language english
228 results on '"Yokoi, Chizu"'

1. A mathematical simulation model to determine the optimal endoscopic screening strategy for detection of H. pylori-naïve gastric neoplasms

Author

Ishibashi, Fumiaki, Okusa, Kosuke, Tokai, Yoshitaka, Hirasawa, Toshiaki, Kawakami, Tomohiro, Mochida, Kentaro, Yanai, Yuka, Yokoi, Chizu, Hayashi, Yuko, Ozawa, Shun-ichiro, Uraushihara, Koji, Minato, Yohei, Nakanishi, Hiroyuki, Ueyama, Hiroya, Kataoka, Mikinori, Toyama, Yuzo, Mizokami, Yuji, and Suzuki, Sho

Published
2024
Full Text
View/download PDF

3. Efficacy of endoscopic submucosal resection with a ligation device for small rectal neuroendocrine tumor: study protocol of a multicenter open-label randomized control trial (BANDIT trial)

Author

Takada, Kazunori, Imai, Kenichiro, Yamada, Takanori, Ohata, Ken, Kanesaka, Takashi, Nagami, Yasuaki, Yamasaki, Yasushi, Kobara, Hideki, Inokuchi, Yasuhiro, Chino, Akiko, Yamaguchi, Shinjiro, Ikehara, Hisatomo, Kawamura, Takuji, Yabuuchi, Yohei, Mizuguchi, Yasuhiko, Ikematsu, Hiroaki, Yokoi, Chizu, Hattori, Santa, Ohno, Kazuya, Yoshizawa, Yashiro, Fukuzawa, Masakatsu, Tsuji, Yosuke, Konishi, Jun, Yamamura, Takeshi, Osawa, Satoshi, Oka, Shiro, Hikichi, Takuto, Togashi, Kazutomo, Hirasawa, Kingo, Uraoka, Toshio, Takeuchi, Yoji, Chiba, Hideyuki, Komeda, Yoriaki, Doyama, Hisashi, Oba, Mari S., and Saito, Yutaka

Published
2024
Full Text
View/download PDF

7. Long-term Survival After Endoscopic Resection For Gastric Cancer: Real-world Evidence From a Multicenter Prospective Cohort

Author

Mashimo, Yumi, Ishigooka, Masahiro, Fukase, Kazutoshi, Mizuguchi, Yasuhiko, Suzuki, Haruhisa, Ono, Hiroyuki, Hirasawa, Toshiaki, Takeuchi, Yoji, Ishido, Kenji, Hoteya, Shu, Yano, Tomonori, Tanaka, Shinji, Toya, Yosuke, Nakagawa, Masahiro, Toyonaga, Takashi, Takemura, Kenichi, Hirasawa, Kingo, Matsuda, Mitsuru, Yamamoto, Hironori, Tsuji, Yosuke, Hashimoto, Satoru, Yuki, Maeda, Oyama, Tsuneo, Takenaka, Ryuta, Yamamoto, Yoshinobu, Naito, Yuji, Yamamoto, Katsumi, Kobayashi, Nozomu, Kawahara, Yoshiro, Hirano, Masaaki, Koizumi, Shigeto, Hori, Shinichiro, Tajika, Masahiro, Hikichi, Takuto, Yao, Kenshi, Yokoi, Chizu, Ohnita, Ken, Hisanaga, Yasuhiro, Sumiyoshi, Tetsuya, Kitamura, Shinji, Tanaka, Hisao, Shimoda, Ryo, Shimazu, Taichi, Takizawa, Kohei, Tanabe, Satoshi, Kondo, Hitoshi, Iishi, Hiroyasu, Ninomiya, Motoki, and Oda, Ichiro

Published
2023
Full Text
View/download PDF

11. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility

Author

Okubo, Hidetaka, Akiyama, Junichi, Kobayakawa, Masao, Kawazoe, Megumi, Mishima, Saori, Takasaki, Yusuke, Nagata, Naoyoshi, Shimada, Takayuki, Yokoi, Chizu, Komori, Shiori, Kimura, Kana, Hisada, Yuya, Iwata, Eri, Watanabe, Kazuhiro, Yanagisawa, Naohiro, Shiroma, Sho, Shimomura, Akira, Okahara, Koki, Cho, Hourin, and Uemura, Naomi

Published
2020
Full Text
View/download PDF

21. Main causes of death in advanced biliary tract cancer.

Author

Kimura‐Seto, Kana, Kojima, Yasushi, Komori, Shiori, Hisada, Yuya, Otake, Yuki, Yanai, Yuka, Saito, Akiko, Akazawa, Naoki, Tanaka, Yasuo, Yokoi, Chizu, Yanase, Mikio, Akiyama, Junichi, Yamamoto, Natsuyo, and Yamada, Kazuhiko

Subjects
BILIARY tract cancer, CAUSES of death, CHOLANGITIS, CANCER invasiveness, LIVER failure, OVERALL survival
Abstract

Background: There are no previous reports on the main causes of death in biliary tract cancer (BTC) patients. This study aimed to evaluate the main causes of death and survival rates in patients with BTC. Methods: We retrospectively evaluated 143 patients who were diagnosed with unresectable BTC between August 2010 and March 2020. We classified the main causes of death based on laboratory data, imaging studies, and medical records. The main causes of death evaluated included liver failure, cholangitis, cachexia, other causes associated with tumor progression, and complications. We also analyzed survival rates for each main cause of death. Results: After excluding patients who were lost to follow‐up, living patients, and patients who had no records of laboratory data within 30 days before the date of death, 108 patients were analyzed. The main cause of death was cholangitis in 33 (30.6%), cachexia in 22 (20.4%), liver failure in 10 (9.3%), other causes associated with tumor progression in 18 (16.7%), and complications in 25 (23.2%) patients. Median overall survival (OS) was 334.0 days in the chemotherapy group and 75.0 days in the best supportive care (BSC) group. Survival analyzed according to the main cause of death was significantly different between the chemotherapy and BSC groups; OS for cachexia, cholangitis, liver failure, other causes associated with tumor progression, and complications, respectively, were 453.0, 499.0, 567.0, 205.0, and 327.5 days (p = 0.003) in the chemotherapy group and 219.0, 69.0, 34.0, 93.0, and 56.0 days (p = 0.001) in the BSC group. Conclusion: The main causes of death in patients with advanced BTC are cholangitis, cachexia, liver failure, other causes associated with tumor progression, and complications. Other causes associated with tumor progression in the chemotherapy group, and liver failure in the BSC group as the main causes of death shortened the survival of BTC patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Abdominal visceral fat accumulation measured by computed tomography associated with an increased risk of gallstone disease

Author

Sekine, Katsunori, Nagata, Naoyoshi, Sakamoto, Kayo, Arai, Tomohiro, Shimbo, Takuro, Shinozaki, Masafumi, Okubo, Hidetaka, Watanabe, Kazuhiro, Imbe, Koh, Mikami, Shintaro, Nozaki, Yuichi, Sakurai, Toshiyuki, Yokoi, Chizu, Kojima, Yasushi, Kobayakawa, Masao, Yanase, Mikio, Akiyama, Junichi, Noda, Mitsuhiko, and Uemura, Naomi

Published
2015
Full Text
View/download PDF

35. Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma

Author

Nagata, Naoyoshi, Sakamoto, Kayo, Arai, Tomohiro, Niikura, Ryota, Shimbo, Takuro, Shinozaki, Masafumi, Aoki, Tomonori, Kishida, Yoshihiro, Sekine, Katsunori, Tanaka, Shohei, Okubo, Hidetaka, Watanabe, Kazuhiro, Sakurai, Toshiyuki, Yokoi, Chizu, Akiyama, Junichi, Yanase, Mikio, Noda, Mitsuhiko, Itoh, Toshiyuki, Mizokami, Masashi, and Uemura, Naomi

Published
2014
Full Text
View/download PDF

39. Su1285 IMPACT OF MEDICATION USE ON THE RISK OF REFLUX ESOPHAGITIS

Author

Ueta, Ren, Tabuchi, Mikio, tonishi, takao, Shinohara, Shintaro, Tatsuno, Naoko, Masuda, Erika, Kimura, Kana, Komori, Shiori, Hisada, Yuya, Otake, Yuki, Yanai, Yuka, Akazawa, Naoki, Kojima, Yasushi, Yokoi, Chizu, Yamamoto, Natsuyo, Saito, Akiko, Tanaka, Yasuo, Yanase, Mikio, and Akiyama, Junichi

Published
2023
Full Text
View/download PDF

42. Conflicting clinical environment about the management of antithrombotic agents during the periendoscopic period in Japan

Author

Ono, Satoshi, Fujishiro, Mitsuhiro, Kanzaki, Hiromitsu, Uedo, Noriya, Yokoi, Chizu, Akiyama, Junichi, Sugawara, Masaki, Oda, Ichiro, Suzuki, Shoko, Fujita, Yoshiyuki, Tsubata, Shunsuke, Hirano, Masaaki, Fukuzawa, Masakatsu, Kataoka, Mikinori, Kamoshida, Toshiro, Hirai, Shinji, Sumiyoshi, Tetsuya, Kondo, Hitoshi, Yamamoto, Yorimasa, Okada, Kazuhisa, Morita, Yoshinori, Fujiwara, Shoko, Morishita, Shinji, Matsumoto, Masao, and Koike, Kazuhiko

Published
2011
Full Text
View/download PDF

43. Glutathione S-transferase omega 2 regulates cell growth and the expression of E-cadherin via post-transcriptional down-regulation of β-catenin in human esophageal squamous cells.

Author

Terayama, Masayoshi, Yamada, Kazuhiko, Hagiwara, Teruki, Inazuka, Fumika, Sezaki, Takuhito, Igari, Toru, Yokoi, Chizu, Nohara, Kyoko, Soma, Daisuke, Dohi, Taeko, and Kawamura, Yuki I

Subjects
CADHERINS, REVERSE transcriptase polymerase chain reaction, CELL growth, GLUTATHIONE
Abstract

Glutathione S -transferase omega 2 (GSTO2), which belongs to the superfamily of GST omega class, lacks any appreciable GST activity. Although GSTO2 exhibits thioltransferase and glutathione dehydrogenase activities, its precise expression and physiological functions are still unclear. In the present study, we found that GSTO2 is exclusively expressed in the basal cell layer in Ki67-negative non-proliferative cells in the human esophageal mucosa. GSTO2 overexpression in esophageal squamous cell carcinoma (ESCC) cell lines inhibited cell growth and colony formation, and GSTO2-transfected cells formed smaller tumors in nude mice compared with mock-transfected cells. Interestingly, GSTO2 induction suppressed the expressions of E-cadherin and β-catenin at the cell–cell contact site. We quantified the phosphorylation levels of key proteins of MAPK signaling pathway and identified phosphorylation of p38. Additionally, HSP27, a downstream molecule of p38, was accelerated in GSTO2-transfected cells, unlike in mock-transfected cells. When GSTO2-transfected cells were treated with a p38 inhibitor, the expression of β-catenin and the membrane localization of E-cadherin was recovered. We next examined GSTO2 expression in 61 ESCC tissues using quantitative reverse transcription polymerase chain reaction and immunostaining. The results showed that GSTO2 mRNA and protein were significantly reduced in ESCC compared with normal tissues. When human ESCC cell lines were treated with 5-aza-2′-deoxycytidine, a DNA-methyltransferase inhibitor, GSTO2 transcription was induced, suggesting that aberrant hypermethylation is the cause of the down-regulated expression. Our results indicate that GSTO2 expression inhibits the membrane localization of E-cadherin, probably by modulation of the p38 signaling pathway. Down-regulation of GSTO2 by DNA hypermethylation contributes to the growth and progression of ESCC. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

44. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.

Author

Akiyama, Junichi, Hosaka, Hiroko, Kuribayashi, Shiko, Moriyasu, Shiori, Hisada, Yuya, Okubo, Hidetaka, Watanabe, Kazuhiro, Imbe, Koh, Nagata, Naoyoshi, Kojima, Yasushi, Yokoi, Chizu, Uemura, Naomi, Shimoyama, Yasuyuki, Kawamura, Osamu, Yamada, Masanobu, and Kusano, Motoyasu

Subjects
POTASSIUM antagonists, GASTRIC acid, PROTON pump inhibitors, H2 receptor antagonists, GASTROESOPHAGEAL reflux, PROTONS
Abstract

Background/Aim: We evaluated the efficacy of vonoprazan (VPZ), a novel potassium-competitive acid blocker, in patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD), exhibiting continued pathological esophageal acid exposure (EAE). Methods: Despite ≥8 weeks of appropriate PPI therapy, patients with -persistent reflux symptoms and pathological EAE times (EAETs ≥4%) were invited to switch to VPZ treatment. After an 8-week-course of once-daily VPZ (20 mg), multichannel intraluminal impedance-pH (MII-pH) monitoring was repeated to compare gastric acid exposure times (GAETs), EAETs, and other reflux parameters relative to the baseline values. Before each MII-pH study, reflux symptom severities were scored using the Gastrointestinal Symptom Rating Scale; erosive esophagitis and fasting plasma gastrin levels were also assessed. Results: From among the 124 patients undergoing MII-pH monitoring, 13 patients (median age, 69 years; females, 64%) were monitored at baseline (while on PPI therapy) and after VPZ therapy. The median GAET associated with VPZ treatment (23.8%) was less than that for PPI treatment (41.1%; p = 0.01), including both daytime and nighttime measurements. VPZ therapy resulted in better median EAET values (4.5%) than did PPI therapy (10.6%) during the 24-h monitoring period (p = 0.055). EAE normalization was achieved in 46% of VPZ-treated patients and was associated with complete gastric acid suppression (p = 0.005). After switching to VPZ, reflux symptoms (p < 0.01) and erosive esophagitis (p = 0.01) improved. Conclusion: In patients with PPI-refractory GERD, VPZ provides more potent gastric acid suppression, more effective EAE control, enhanced symptom improvement, and better esophagitis healing than PPIs. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

46. Mo1335 DETECTION OF EARLY GASTRIC CANCER USING SECOND-GENERATION NARROW BAND IMAGING: A MULTICENTER RANDOMIZED CONTROLLED TRIAL

Author

Ito, Renma, Yoshida, Naohiro, Doyama, Hisashi, Oono, Yasuhiro, Yano, Tomonori, Horimatsu, Takahiro, Uetake, Hiroyuki, Yamamoto, Yoshinobu, Kakushima, Naomi, Kanzaki, Hiromitsu, Hori, Shinichiro, Yao, Kenshi, Oda, Ichiro, Tanabe, Satoshi, Yokoi, Chizu, Ohata, Ken, Yoshimura, Ken-ichi, Ishikawa, Hideki, and Muto, Manabu

Published
2019
Full Text
View/download PDF

48. Acinar Cell Carcinoma of the Pancreas with Colon Involvement

Author

Asayama, Naoki, Kojima, Yasushi, Aoki, Tomonori, Maeyashiki, Chiaki, Yokoi, Chizu, Yanase, Mikio, Suda, Ryuichiro, Yano, Hideaki, Nakamura, Harumi, and Igari, Toru

Subjects
Article Subject
Abstract

We report a case of acinar cell carcinoma of the pancreas with colon involvement that was difficult to distinguish from primary colon cancer. A 60-year-old man was admitted with a 1-month history of diarrhea. Contrast-enhanced computed tomography (CT) revealed a large tumor (10.6×11.6 cm) at the splenic flexure of the colon. Colonoscopy showed completely round ulcerative lesions, and biopsy revealed poorly differentiated adenocarcinoma. Left hemicolectomy, resection of the jejunum and pancreas body and tail, and splenectomy were performed based on a diagnosis of descending colon cancer (cT4N0M0, stage IIB), and surgery was considered to be curative. Diagnosis was subsequently confirmed as moderately differentiated acinar cell carcinoma of the pancreas by immunohistochemical staining (pT3N0M0, stage IIA). Multiple liver metastases with portal thrombosis were found 8 weeks postoperatively. Despite combination chemotherapy with oral S-1 and gemcitabine, the patient died of hepatic failure with no effect of chemotherapy 14 weeks postoperatively. Correct diagnosis was difficult to determine preoperatively from the clinical, CT, and colonoscopy findings. Moreover, the disease was extremely aggressive even after curative resection. Physicians should consider pancreatic cancer in the differential diagnosis of similar cases.

Published
2014
Full Text
View/download PDF

49. Tu1298 - Vonoprazan-Based Triple Therapy is Effective for Helicobacter Pylori Eradication Irrespective of Clarithromycin Susceptibility

Author

Okubo, Hidetaka, Akiyama, Junichi, Kobayakawa, Masao, Kawazoe, Megumi, Mishima, Saori, Takasaki, Yusuke, Nagata, Naoyoshi, Shimada, Takayuki, Yokoi, Chizu, Moriyasu, Shiori, Kimura, Kana, Hisada, Yuya, Kihira, Eri, Watanabe, Kazuhiro, Yanagisawa, Naohiro, Shiroma, Shou, Shimomura, Akira, Okahara, Kouki, Cho, Hourin, and Uemura, Naomi

Published
2018
Full Text
View/download PDF

50. Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding.

Author

Nagata, Naoyoshi, Sakurai, Toshiyuki, Moriyasu, Shiori, Shimbo, Takuro, Okubo, Hidetaka, Watanabe, Kazuhiro, Yokoi, Chizu, Yanase, Mikio, Akiyama, Junichi, and Uemura, Naomi

Subjects
GASTROINTESTINAL disease diagnosis, GASTROINTESTINAL disease treatment, BLOOD coagulants, HEPARIN antagonists, THROMBOEMBOLISM, GENETICS, THERAPEUTICS
Abstract

Background: Anticoagulant management of acute gastrointestinal bleeding (GIB) during the pre-endoscopic period has not been fully addressed in American, European, or Asian guidelines. This study sought to evaluate the risks of rebleeding and thromboembolism in anticoagulated patients with acute GIB. Methods: Baseline, endoscopy, and outcome data were reviewed for 314 patients with acute GIB: 157 anticoagulant users and 157 age-, sex-, and important risk-matched non-users. Data were also compared between direct oral anticoagulants (DOACs) and warfarin users. Results: Between anticoagulant users and non-users, of whom 70% underwent early endoscopy, no endoscopy-related adverse events or significant differences were found in the rate of endoscopic therapy need, transfusion need, rebleeding, or thromboembolism. Rebleeding was associated with shock, comorbidities, low platelet count and albumin level, and low-dose aspirin use but not HAS-BLED score, any endoscopic results, heparin bridge, or international normalized ratio (INR) ≥ 2.5. Risks for thromboembolism were INR ≥ 2.5, difference in onset and pre-endoscopic INR, reversal agent use, and anticoagulant interruption but not CHA2DS2-VASc score, any endoscopic results, or heparin bridge. In patients without reversal agent use, heparin bridge, or anticoagulant interruption, there was only one rebleeding event and no thromboembolic events. Warfarin users had a significantly higher transfusion need than DOACs users. Conclusion: Endoscopy appears to be safe for anticoagulant users with acute GIB compared with non-users. Patient background factors were associated with rebleeding, whereas anticoagulant management factors (e.g. INR correction, reversal agent use, and drug interruption) were associated with thromboembolism. Early intervention without reversal agent use, heparin bridge, or anticoagulant interruption may be warranted for acute GIB. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results